Beigene is a global oncology company that was built differently to deliver innovative medicines faster, more equitably and affordably around the world. We are an oncology powerhouse with a deep, diverse pipeline fueled by one of the industry’s largest and most productive research teams. Our two foundational medicines, BTK inhibitor BRUKINSA® (zanubrutinib) and PD-1 inhibitor TEVIMBRA® (tislelizumab), demonstrate the strength of our science and our mission to improve treatment outcomes for patients. More than 1 million patients have been treated with our medicines, reflecting our expansive global reach and deep commitment to access.

YouTube: http://www.youtube.com/@beigene